Search

439 results for "lecanemab".

Research summaries 393

Showing the best 200 of 393, 21–30, page 3 of 20. Filter these by subject, year and score in the research library →

1. Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the Clarity AD open-label extension studyResearch summary

   Research summaries · alzhub.org/study/long-term-safety-and-efficacy-of-lecanemab-in-early-alzheimer-s-41355080

   Introduction In Clarity AD, lecanemab reduced markers of amyloid in early symptomatic Alzheimer's disease and slowed cognitive and functional decline at 18 months. Herein, we report 36-month data from the ongoing open-label …

2. Lecanemab (Leqembi)Research summary

   Research summaries · alzhub.org/study/lecanemab-leqembi-25dfc5ad

   Canada’s Drug Agency (CDA-AMC) recommends that Leqembi be reimbursed by public drug plans for the treatment of adult patients in the early stages of Alzheimer disease (AD) (i.e., mild cognitive impairment [MCI] or mild dementia) …

3. Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/clarity-ad-asian-regional-analysis-of-a-phase-iii-trial-of-lecanemab-40189473

   … Singapore:13). The efficacy of lecanemab was consistent with the overall population. For the primary endpoint, there was a slowing of decline with lecanemab in the CDR-SB at 18 months compared to placebo in the Asian region …

4. Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?Research summary

   Research summaries · alzhub.org/study/implications-of-the-approval-of-lecanemab-for-alzheimer-disease-37295957

   … 3 clinical trial of lecanemab have reported clinical benefits linked to amyloid removal. Lecanemab (trade name, Leqembi) is the first with published phase 3 trial results. When administered through IV every 2 weeks to patients …

5. Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer DiseaseResearch summary

   Research summaries · alzhub.org/study/lecanemab-a-humanized-monoclonal-antibody-for-the-treatment-of-early-38095619

   … safety, and efficacy of lecanemab in patients with Alzheimer disease. Data sources A literature search of PubMed (April 1, 2016-November 15, 2023) and ClinicalTrials.gov search were conducted using the following search terms: …

6. Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical TrialResearch summary

   Research summaries · alzhub.org/study/lecanemab-for-patients-with-early-alzheimer-disease-bayesian-analysis-37040116

   … 587 were assigned to a lecanemab 201 treatment group (median age, 72 years [range, 50-90 years]; 272 female [46%]). The bayesian approach improved the efficiency of a clinical trial by prospectively adapting to the trial's …

7. Lecanemab in Early Alzheimer's DiseaseResearch summary

   Research summaries · alzhub.org/study/lecanemab-in-early-alzheimer-s-disease-22dd8fce

   This is the primary Phase 3 Clarity AD trial report for lecanemab. In 1,795 people with early Alzheimer's disease randomized to lecanemab or placebo every two weeks for 18 months, lecanemab slowed decline on the main …

8. Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer DiseaseResearch summary

   Research summaries · alzhub.org/study/cost-effectiveness-of-lecanemab-for-individuals-with-early-stage-38484190

   … cost-effectiveness of lecanemab (Leqembi), a monoclonal antibody approved by the US Food and Drug Administration in January 2023 for the treatment of mild cognitive impairment (MCI) or mild dementia due to Alzheimer disease (AD). …

9. Lecanemab Treatment in a Specialty Memory ClinicResearch summary

   Research summaries · alzhub.org/study/lecanemab-treatment-in-a-specialty-memory-clinic-40354064

   … patients treated with lecanemab had a mean age of 74.4 (SD, 6.7) years, 117 were female (50%), and 117 were male (50%). Overall, 23 of 234 patients (9.8%) withdrew from treatment for various reasons, 10 for ARIA (4.3%). The …

10. Lecanemab in Singapore: Appropriate use recommendations for early Alzheimer's diseaseResearch summary

    Research summaries · alzhub.org/study/lecanemab-in-singapore-appropriate-use-recommendations-for-early-42995156

    Introduction Lecanemab, a monoclonal antibody targeting β-amyloid oligomers, protofibrils, and insoluble fibrils, has been approved for Alzheimer's disease (AD) treatment in Singapore, based on the phase 3 Clarity AD study. In …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.